ニツタ　コウサク   Nitta Kosaku   新田　孝作    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study
掲載誌名	正式名：Clinical kidney journal. 略　 称：Clin Kidney J ISSNコード：20488505/20488513
巻・号・頁	15(3),pp.473-483
著者・共著者	Abe Masanori, Masakane Ikuto, Wada Atsushi, Nakai Shigeru, Nitta Kosaku, Nakamoto Hidetomo
発行年月	2021/09/28
概要	Introduction: In Japan, dialyzers are classified based on β2-microglobulin clearance. Type I dialyzers are classified as low-flux dialyzers (<10 mL/min clearance), type II and III as high-flux dialyzers (≥10 to <30 mL/min and ≥30 to <50 mL/min clearance, respectively), and type IV and V as super high-flux dialyzers (≥50 to <70 mL/min and ≥70 mL/min clearance, respectively). Super high-flux dialyzers are commonly used, but their superiority over low-flux dialyzers is controversial. Methods: In this nationwide prospective cohort study, we analyzed Japanese Society for Dialysis Therapy Renal Data Registry data collected at the end of 2008 and 2011. We enrolled 242,467 patients on maintenance hemodialysis and divided them into five groups by dialyzer type. We assessed the associations of each dialyzer type with 3-year all-cause mortality using Cox proportional hazards models and performed propensity score matching analysis, adjusting for potential confounders. Results: By the end of 2011, 53,172 (21.9%) prevalent dialysis patients had died. Mortality significantly decreased according to dialyzer type. Hazard ratios (HRs) were significantly higher for type I, II and III compared with type IV (reference) after adjustment for basic factors and further adjustment for dialysis-related factors. HR was significantly higher for type I, but significantly lower for type V, after further adjustment for nutrition- and inflammation-related factors. These significant findings were also evident after propensity score matching. Conclusions: Hemodialysis using super high-flux dialyzers might reduce mortality. Randomized controlled trials are warranted to clarify whether these type V dialyzers can improve prognosis.
DOI	10.1093/ckj/sfab177.
PMID	35211304